Advanced search
Publication Cover
Current Medical Research and Opinion Volume 25, 2009 - Issue 2
Submit an article Journal homepage
225
Views
14
CrossRef citations to date
0
Altmetric
Original Article

Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and Medicare-eligible populations*

Kavita V. Nair University of Colorado Denver, Aurora, CO, USACorrespondence[email protected]
,
Boxiong Tang Centocor, Inc., Horsham, PA, USA
,
Jill Van Den Bos Milliman, Inc., Denver, CO, USA
,
Vicki Zhang Milliman, Inc., Denver, CO, USA
,
Joseph J. Saseen University of Colorado Denver, Aurora, CO, USA
,
Ahmad Naim Centocor, Inc., Horsham, PA, USA
&
Mirza Rahman Centocor, Inc., Horsham, PA, USA
 show all
Pages 303-314 | Accepted 04 Nov 2008, Published online: 12 Dec 2008

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

J. Harnett, D. Wiederkehr, R. Gerber, D. Gruben, A. Koenig & J. Bourret. (2016) Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis. Journal of Medical Economics 19:2, pages 101-112.
Read now
Chureen T. Carter, Arun K. Changolkar & R. Scott McKenzie. (2012) Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients. Journal of Medical Economics 15:2, pages 332-339.
Read now
Heidi Waters, Julie Vanderpoel, Scott McKenzie, Orsolya Lunacsek, Meg Franklin, Barbara Lennert, John Goff & Damian H. Augustyn. (2011) Stability of infliximab dosing in inflammatory bowel disease: results from a multicenter US chart review. Journal of Medical Economics 14:4, pages 397-402.
Read now

Articles from other publishers (11)

Christopher J. Edwards, Mauro Galeazzi, Salvatore Bellinvia, Ariana Ringer, Theodoros Dimitroulas & George Kitas. (2019) Can we wean patients with inflammatory arthritis from biological therapies?. Autoimmunity Reviews 18:12, pages 102399.
Crossref
Chak Sing Lau, Allan Gibofsky, Nemanja Damjanov, Sadiq Lula, Lisa Marshall, Heather Jones & Paul Emery. (2017) Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review. Rheumatology International 37:11, pages 1789-1798.
Crossref
Gundula Krack, Henning Zeidler & Jan Zeidler. (2016) Claims Data Analysis of Tumor Necrosis Factor Inhibitor Treatment Dosing Among Patients with Rheumatoid Arthritis: A Systematic Review of Methods. Drugs - Real World Outcomes 3:3, pages 265-278.
Crossref
Naonobu Sugiyama, Yutaka Kawahito, Takao Fujii, Tatsuya Atsumi, Tatsunori Murata, Yosuke Morishima & Yuri Fukuma. (2016) Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data. Clinical Therapeutics 38:6, pages 1359-1375.e1.
Crossref
Rafael Ferriols-Lisart & Francisco Ferriols-Lisart. (2015) Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review. Rheumatology International 35:7, pages 1193-1210.
Crossref
Stephen S. Johnston, Donna McMorrow, Amanda M. Farr, Paul Juneau & Sarika Ogale. (2015) Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated with Infused Biologics After Switching from Another Biologic. Drugs - Real World Outcomes 2:1, pages 99-109.
Crossref
Stephen S. Johnston, Adam Turpcu, Nianwen Shi, Robert Fowler, Bong-Chul Chu & Kimberly Alexander. (2013) Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis. Seminars in Arthritis and Rheumatism 43:1, pages 39-47.
Crossref
Susan C. Bolge, Chureen T. Carter, Cynthia S. Mueller, Robert A. Bailey & Michael P. Ingham. (2012) Comparative Multidatabase Analysis of Dosing Patterns and Infusion Intervals for the First 12 Infliximab Infusions in Patients With Rheumatoid Arthritis. Clinical Therapeutics 34:12, pages 2286-2292.
Crossref
Jeffrey R. Curtis, Angel Lanas, Ani John, David A. Johnson & Kathy L. Schulman. (2012) Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. Arthritis Care & Research 64:12, pages 1819-1828.
Crossref
Sarika Ogale, Elena Hitraya & Henry J Henk. (2011) Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskeletal Disorders 12:1.
Crossref
Ryan Mayhew, June M. McKoy, Thanh Ha Luu, Isaac Lopez, Melissa Frick & Charles L. Bennett. (2010) Adverse Drug Interactions. PharmacoEconomics 28:1, pages 19-22.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.